Article Text

PDF

Tenascin-C expression in normal, inflamed, and scarred human corneas
  1. H Maserukaa,b,
  2. R E Bonsheka,b,
  3. A B Tullob
  1. aDepartment of Pathological Sciences, University of Manchester, bDepartment of Ophthalmology, Manchester Royal Eye Hospital
  1. Dr Richard E Bonshek, Department of Ophthalmology, University of Manchester, Royal Eye Hospital, Oxford Road, Manchester M13 9WH.

Abstract

AIMS/BACKGROUND In adult tissues the expression of tenascin-cytotactin (TN-C), an extracellular matrix glycoprotein, is limited to tumours and regions of continuous renewal. It is also transiently expressed in cutaneous and corneal wound healing. There are limited data regarding its expression in inflammation and scarring of the adult human cornea. In this study, TN-C expression patterns in normal, inflamed, and scarred human corneas have been examined.

METHODS Penetrating keratoplasty specimens were selected from cases of herpes simplex keratitis, herpes zoster ophthalmicus, rheumatoid arthritis ulceration, bacterial keratitis, rosacea keratitis, interstitial keratitis, and previous surgery so as to encompass varying degrees of active and chronic inflammation and scarring. TN-C in these and in normal corneas was immunodetected using TN2, a monoclonal antibody to human TN-C.

RESULTS There was no TN2 immunopositivity in normal corneas except at the corneoscleral interface. In pathological corneas, TN2 immunopositivity was localised in and around regions of active inflammation, fibrosis, and neovascularisation. TN2 positivity was less in acute inflammation than in active chronic inflammation. Mature, avascular scar tissue and epithelial downgrowth were TN2 negative.

CONCLUSION These results indicate that in the adult human cornea, TN-C expression is induced in regions of inflammation, fibrosis, and neovascularisation, but that expression is absent in mature, avascular scar tissue. This suggests a role for this glycoprotein in inflammation, healing, and extracellular matrix reorganisation of the cornea.

  • tenascin-cytotactin (TN-C)
  • cornea
  • inflammation
  • scarring

Statistics from Altmetric.com

Tenascin is a large extracellular matrix glycoprotein (∼190–320 kD)1 which has been described variously as cytotactin,2 glioma-myotendinous associated extracellular matrix (GMEM) protein,3 myotendinous antigen,4 hexabranchion,5 and J1-200/220.6 Currently, this glycoprotein is referred to as tenascin-cytotactin (TN-C).7

Several in vitro studies have shown that TN-C mediates a number of cellular activities. For example, it stimulates89 and inhibits910 the proliferation of cells. It also interacts with fibronectin (FN), and supports adhesion of a variety of cell types including fibroblasts, glia, neurons, and endothelial cells.11-13 Paradoxically, antiadhesive properties have also been described,1213 providing evidence for multifunctionality of this glycoprotein.

TN-C shows a time and tissue specific expression in the developing embryo. It is, for example, present at the epithelial mesenchyme interfaces of skin, oral mucosa, lung, genitourinary tract, gastrointestinal tract, kidney, breast, and in the developing brain and cornea.281415 In adult tissues TN-C expression is limited to tumours, regions of continuous renewal, and wound healing (reviewed by Sakakura and Kusano16).

Although TN-C is expressed in developing human fetal cornea,15 in normal adult human cornea very low expression has been demonstrated in corneal epithelial cells only,17with a greater degree of expression at the limbal region.1718 In rabbits, however, TN-C has been detected in the entire normal corneal epithelium, but it is absent in the stroma.19-21 As seen in cutaneous wound healing,2223 TN-C is transiently expressed in corneal wound healing.1719-21 However, to date there are limited data regarding the expression of TN-C in both normal and pathological adult human corneas. This, together with a body of evidence supporting a role for this glycoprotein in influencing several cellular activities,268-1315 prompted us to examine TN-C expression in inflamed, vascularised, and scarred human corneas. Comparison of patterns of TN-C localisation in pathological and normal corneas was aimed at determining whether a relation exists between the progression of events in inflammation, healing, and scarring, and TN-C expression in the human cornea.

Materials and methods

Thirty five corneal specimens obtained from patients aged from 3 to 97 years, who had undergone penetrating keratoplasty, were selected to encompass varying degrees of acute and chronic inflammation, and scarring. These included the following cases—bacterial keratitis (three); herpes simplex keratitis (HSK) (10); rosacea keratitis (three); herpes zoster ophthalmicus (HZO) (five); interstitial keratitis (IK) (seven); rheumatoid arthritis (RA) ulceration (five); and previous surgery (two). Ten globes enucleated for choroidal melanoma but without anterior segment pathology provided normal corneas. All tissues were fixed in 10% (v/v) phosphate buffered formalin, pH 7.4, before being dehydrated and embedded in paraffin wax.

Reagents and antibodies employed in the study are shown in Table 1. A mouse anti-human TN-C (clone TN2, isotype IgG1, kappa) obtained from Dako, UK, was employed in this study. TN2 has been employed in a number of studies investigating tissue distribution of TN-C.1824

Table 1

Source of reagents and antibodies employed

Microtome sections (6 μm), mounted on 3-aminopropyl-triethoxy silane (APES) coated slides, were dewaxed in xylene and rehydrated in graded (99%–70% (v/v)) industrial methylated spirit (IMS). Endogenous peroxidase activity was quenched by a 30 minute incubation with 1% (v/v) hydrogen peroxide (H2O2), and antigenic sites unmasked by incubation with 1 mg/ml trypsin in 4 mM CaCl2 and 200 mM TRIS, pH 7.6 (10 minutes, 37°C). A solution of 20% (v/v) normal rabbit serum (NRS) was applied to sections (15 minutes, 25°C) to block non-specific binding sites. The NRS was then tipped off and sections incubated overnight (4°C) with a 1:25 (v:v) TN2. Bound TN2 was detected by applying 1:100 (v:v) biotinylated rabbit anti-mouse immunoglobulins (30 minutes, 25°C). This was then visualised by incubating sections (30 minutes, 25°C) with a solution of avidin-biotin horseradish peroxidase complex (ABC/HRP) and reacting with a 3,3’diaminobenzidine (DAB) tetrachloride/H2O2 substrate. Sections were counterstained with Harris’s haematoxylin, dehydrated in graded (70%–99% (v/v)) IMS and cleared in xylene before mounting coverslips with xylene anti-mouse IgG (XAM). Sections were viewed under a routine light microscope.

Between incubation steps, sections were dip immersion washed (2 × 3 minutes) in 0.05 M TRIS buffered saline, pH 7.6, to eliminate excess non-bound antibody or reagent. Negative controls included substitution of TN2 with an irrelevant antibody (mouse anti-human desmin, clone D33, isotype IgG1, kappa), and with 25% (v/v) NRS. No immunoreaction was observed in negative controls. Skin from a case of chronic dermatitis and sclera provided TN2 positive immunoreaction controls.

Results

TN2 immunoreaction was negative in all the normal corneas except at the corneoscleral interface (Fig 1), where sclera was positive. Generally, in all the TN2 positive corneas, stromal staining was seen mostly in an extracellular location. In cases of bacterial keratitis, TN2 was strongly positive in corneal stroma around the periphery of areas of acute inflammation and areas of active ulceration (Figs 2 and3). In areas away from the main focus of inflammatory activity and where there was separation of epithelium from stroma, there was increased subepithelial staining (Fig 2). At higher magnification (Fig3) focal TN2 staining was seen in occasional keratocytes/fibroblasts in acutely inflamed tissue. It was apparent that much of the intense stromal TN2 immunoreaction around the inflamed areas was associated with chronic inflammatory cell infiltrate, although the infiltrating cells were themselves negative. An intermittent line of staining was also seen at the junction between Descemet’s membrane and the posterior stroma (Fig 3).

Figure 1

Normal cornea and corneoscleral interface. There is TN2 immunopositivity of the sclera (small arrows) including the scleral spur (large arrow). Corneal tissue is TN2 immunonegative (× 18).

Figure 2

Bacterial keratitis, with ulcer and stromal abscess. Strong TN2 immunopositivity in and around the edges of the acutely inflamed tissue. The ulcer, epithelium, and stroma immediately adjacent are negative. There is also subepithelial TN2 immunopositivity in an area of epithelial lifting from oedematous stroma (small arrows) (× 38).

Figure 3

Bacterial keratitis, higher magnification. Occasional TN2 positive keratocytes are seen in the acutely inflamed area. However, the strongest TN2 immunoreaction is in the posterior stroma where there is a chronic inflammatory cell infiltrate, rather than in the acutely inflamed tissue of mid stroma. The chronic inflammatory cells are negative, but the stromal tissue is positive. Note that Descemet’s membrane is negative, but there is a band of TN2 immunopositivity at the interface between posterior stroma and Descemet’s membrane (arrowheads). Endothelium has been lost from this cornea (× 185).

Cases of HSK, rosacea keratitis, and HZO showed heterogeneity of stromal staining for TN2. However, in all cases there was stromal TN2 immunoreactivity associated with active chronic inflammation (Fig 4). As in the chronic inflammation around the area of acute inflammatory activity shown in Figures 2 and 3, the inflammatory cells were TN2 negative, and there was focal positivity of the stroma/Descemet’s membrane interface. There was no difference in the patterns of TN2 staining seen with respect to any of these three aetiologies.

Figure 4

Herpes simplex keratitis cornea. There is stromal TN2 immunopositivity associated with chronic inflammation in the posterior stroma. Inflammatory cells are negative. Note that, as in Figure 3, there is also focal positivity at the interface between posterior stroma and Descement’s membrane (arrowheads). Endothelium is intact (× 370).

IK corneas were negative except for occasional vessels where there was weak TN2 immunopositivity in vascular endothelial cells (not shown). In the majority of RA corneas there were few infiltrating inflammatory cells and there was focal faint TN2 immunostaining associated with these cells. One RA cornea had perforated and contained a strip of intact epithelium which spanned the perforation. This cornea showed strong TN2 positivity in stroma adjacent to the perforation, especially in early subepithelial fibrous scar tissue, and in basement membrane-like material which lay beneath epithelium spanning the defect and which was devoid of substratum (Fig5).

Figure 5

Rheumatoid perforation with an area of epithelium bridging a stromal defect. There is diffuse, extracellular, stromal TN2 immunopositivity around the defect. The small amount of subepithelial tissue remaining beneath the undermined epithelium is also strongly positive (small arrows). Iris pigment (IP) is present as discrete deposits in the posterior stroma below and adjacent to the perforation. Very few inflammatory cells are present (× 38).

In corneas with previous surgery there was TN2 immunostaining in regions of active scar tissue, associated with some chronic inflammatory cells, where stromal and lymphocyte cytoplasmic membrane staining was seen, and some vascular endothelial cells, where there was intracytoplasmic staining (Fig 6). However, where scars were uncomplicated, no TN2 immunopositivity was seen (Fig 7). In one case with an epithelial downgrowth, but with no scarring, TN2 immunoreaction was negative (Fig 8). In some pathological corneas, without any specificity for any disease type, occasional epithelial cells showed granular epithelial cytoplasmic TN2 immunostaining (Figs 6 and7).

Figure 6

Previous surgery. There is patchy chronic inflammation and vascularisation. TN2 immunopositivity is present in the stroma where there is an aggregate of chronic inflammatory cells. Here, occasional lymphocytes have cytoplasmic membrane staining. Elsewhere, there is cytoplasmic labelling of some vascular endothelial cells. There is also granular cytoplasmic staining of epithelial cells overlying this area (× 450, oil immersion).

Figure 7

Healed 2 year old surgical incision. There is minimal fibroblastic reaction and no vascularisation or inflammation. TN2 immunoreaction is negative in the mature scar tissue (arrows). There is faint granular TN2 immunopositivity in the epithelium above the scar (× 450, oil immersion).

Figure 8

Epithelial downgrowth that fills a previous relaxing incision. TN2 immunoreaction is negative in both stroma and epithelium (× 180, differential interference contrast (DIC)).

Discussion

Tenascin was not detected in normal human corneal structures except at the corneoscleral interface. This observation is consistent with the findings of Uusitalo18 who employed the same antibody (clone TN2) which recognises all TN-C variants. However, Tervoet al, have reported immunodetectable TN-C in normal human corneal epithelium, but in agreement with our observation, these authors noted a greater localisation of TN-C at the corneoscleral margin.17 It is unfortunate that their description of corneal epithelial staining is found only in the abstract of their paper and is not mentioned in either the results or discussion, nor do the photomicrographs illustrate this corneal epithelial staining. These authors employed a different monoclonal antibody (100EB2), which recognises an epitope within a conserved FN type III repeat region of the TN-C molecule.25 Thus differences in epitope specificity may be involved, or there may be differences due to masking of epitopes because of fixation, as they used an immunofluorescence method with fresh tissue. We have recently used BC4, a monoclonal antibody described by Siri et al,125 with results identical to those of TN2 (unpublished observations). Species differences in TN-C expression exist, as TN-C has also been immunodetected in the entire epithelium of normal rabbit corneas.19-21 In pathological corneas and those with previous surgery, localisation of TN-C was observed around active ulcers and foci of acute inflammation, within chronically inflamed tissue and granulation tissue, and in vascularised regions. Old/mature avascular scar tissue was TN-C negative.

The absence of TN-C in normal corneas, its expression in inflammation and neovascularisation, and its disappearance in quiescent fibrosis, as seen in mature scar tissue, mirrors the situation described in cutaneous and experimental corneal wound healing.1719-23 In cryptogenic fibrosing alveolitis (CFA), TN-C expression has also been reported in areas of inflammation and active disease but not in end stage scarred tissue.24Of interest, the heterogeneity of TN-C expression which is a feature seen in our HSK, rosacea, and HZO corneas was also observed in CFA.24 Moreover, there was no difference in the patterns of staining which could be ascribed to a viral aetiology. Morphologically, there are no histological features which allow an aetiological distinction between chronic HSK, rosacea, or HZO; thus, the TN-C immunoreactivity observed presumably reflects factors associated with the chronic inflammatory response, fibrosis, and neovascularisation common to these conditions. Data from in vitro and tissue distribution studies have implicated TN-C in signalling cells to alter the expression of genes involved in extracellular matrix (ECM) synthesis and remodelling processes as seen in wound healing.23 TN-C is produced by cultured fibroblasts,23 and an upregulation of synthesis of proteolytic enzymes, such as collagenase, stromelysin, and the 92 kDa gelatinase is commonly observed in fibroblasts plated on a mixed substrate of fibronectin and TN-C.26 TN-C expressed around ulcers and acute inflammation, and in chronically inflamed and fibroblastic areas of these corneas, possibly modulates ECM remodelling during the healing and repair processes which are a component of the chronic inflammatory response. This is supported by the absence of TN-C in quiescent, burnt out scars.

On the other hand, it has been suggested that TN-C acts as an immunomodulator by altering the adhesion of monocytes and B and T lymphocytes.2728 Stromal TN2 positivity was strongest in areas of chronic inflammatory activity and the observation of occasional lymphocyte cytoplasmic membrane TN2 positivity in areas of stromal TN2 positivity in post surgical scarring and vascularisation (Fig 6) would be consistent with TN-C bound to cell surface receptors. Certainly, these cells would be recruited in the transition from the acute to the chronic phase of the inflammatory response.

The focal TN-C expression seen in vascular endothelial cells and in surrounding stroma in some of the HSK, rosacea keratitis, and IK corneas, and in some active scar tissue may support suggestions that TN-C is expressed in activated vascular endothelial cells.29 TN-C expression has been reported in tissue surrounding hyperplastic capillaries around tumours.2930There is also evidence from in vitro studies that capillary endothelial cell morphology and behaviour are influenced by TN-C present in underlying medium via an integrin dependent process.31Antibodies to TN-C have also been shown to inhibit angiogenesis in vitro.32 Our observed TN2 positivity around the periphery of areas of acute inflammation and ulceration may, therefore, be consistent with a role for TN-C in promoting angiogenesis and vascular proliferation.

The observed strong subepithelial TN2 staining in the rheumatoid arthritis (RA) cornea where the epithelium is detached (Fig 2) is of considerable interest. In this situation there appears to be increased TN-C expression by the epithelial cells, with immunolocalisation in the extracellular basement membrane (EBM) zone, which is thickened. A similar appearance is seen in a case of bacterial keratitis (Fig 2) where the epithelium has partially lifted from oedematous stroma. These findings, also reported in dermo-epidermal separation of human skin,33 indicate that TN-C expression is induced in situations where there is loss of attachment of epithelium to substratum. This may suggest that the epithelium is the source of TN-C in these cases. The granular cytoplasmic TN2 staining in the epithelium of several of the pathological corneas could also be interpreted in this way and may be consistent with the observations of Tervo et al.17 TN-C is known to bind to proteoglycans which are basement membrane components13; thus, the TN2 positivity seen in the EBM zone and at the interface between Descemet’s membrane and the posterior stoma may reflect this property.

Our findings, together with the body of data regarding the structure of TN-C and its expression in a variety of tissues during development, in wound healing events, and in pathological states, indicate a functional role for this molecule. The development of the ‘tenascin gene knockout mouse’, which develops normally despite an absent functional tenascin gene,34 presents a paradox, appearing to contradict this evidence. However, a number of gene deletions in mice have resulted in surprisingly mild or undetectable phenotypic alterations35-40 and, even in cases where a mutant mouse mimics a human disease, the mutant mouse does not always provide an exact model for the aetiology and pathogenetic mechanisms (reviewed by Smithies41). Furthermore, other members of the tenascin family (reviewed by Chiquet-Ehrismann et al7) might compensate for the loss of one component.

In conclusion, the patterns of TN-C expression observed in this study indicate that in the human adult cornea, TN-C is induced in inflammatory states, especially where there appears to be fibroblastic activity, and that it is not expressed in mature avascular scar tissue. This pattern of expression suggests an important role for this glycoprotein in inflammation, healing, and in the extracellular matrix remodelling of the human cornea.

Acknowledgments

This study was supported by a North West Regional Health Authority grant and Manchester Royal Eye Hospital Endowments.

References

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.